+

WO2003059297A2 - Dermatological topical compositions and a process for the preparation thereof - Google Patents

Dermatological topical compositions and a process for the preparation thereof Download PDF

Info

Publication number
WO2003059297A2
WO2003059297A2 PCT/SK2003/000002 SK0300002W WO03059297A2 WO 2003059297 A2 WO2003059297 A2 WO 2003059297A2 SK 0300002 W SK0300002 W SK 0300002W WO 03059297 A2 WO03059297 A2 WO 03059297A2
Authority
WO
WIPO (PCT)
Prior art keywords
weight
topical compositions
amount
contain
dermatological topical
Prior art date
Application number
PCT/SK2003/000002
Other languages
French (fr)
Other versions
WO2003059297A8 (en
WO2003059297A3 (en
Inventor
Olǵa SÁKOVÁ
Ružena SOCHOROVÁ
Ivan Varga
Mikuláš LEHOCK
Original Assignee
Slovakofarma A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Slovakofarma A.S. filed Critical Slovakofarma A.S.
Priority to AU2003216034A priority Critical patent/AU2003216034A1/en
Publication of WO2003059297A2 publication Critical patent/WO2003059297A2/en
Publication of WO2003059297A3 publication Critical patent/WO2003059297A3/en
Publication of WO2003059297A8 publication Critical patent/WO2003059297A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4933—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having sulfur as an exocyclic substituent, e.g. pyridinethione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair

Definitions

  • Dermatological topical compositions and a process for the preparation thereof
  • the invention pertains to the field of manufacture of the dermatological topical compositions based on use of substances having antimycotic activity, which are characterized in fungistatic to fungicidal activity against dermatophytes, yeasts, and moulds.
  • the group of therapeutic compositions in the topic form, destined to be applied to the hair covering the head skip includes a variety of shampoos, lotions, hair solutions, and other types of preparations which, after having been applied, are washed off with water. Upon application, they form foam with water. They can have the structure of an emulsion, suspension, solution, with one or more active substances in a suitable carrier and other auxiliary substances, such as surfactants, anti-microbial substances, stabilizers, viscosity regulators, antioxidants, etc.
  • the shampoos contain three types of components: primary surfactants, secondary surfactants, and auxiliary substances.
  • the group of primary surfactants is responsible for the detergency and cleaning of hair, the secondary ones support the detergency.
  • the substances from the third group are added in order to reach special effects and include anti-microbial active substances against the occurrence of dandruff, substances for sedation and maintaining balance of the head skin, etc.
  • Alkyl-sulfates and alkyl-ether-sulfates are used as the basic surfactants Milan Chalabala et al, TECH leku ("Medicament Technology"), 1997/.
  • the secondary group of surfactants is added to improve the detergency, to foster the foam stability, to increase the solubilization of the fragrances and hydrophobic substances.
  • Use of secondary anionic and non-ionic surfactants in shampoos facilitates the detergency of the primary surfactants, but they tend to hydrolyze while being stored, and when applied to the hair the same becomes rough and easily gets a static charge.
  • the surface mycoses are being treated with azole derivatives in compliance with the WHO recommendations.
  • bifonazole is similar to clotrimazole, econazolej miconazole or climbazole, but - unlike them - it does not contain any halogen, and is therefore suitable for the skin.
  • fungicidal activity has been demonstrated in numerous clinical studies in the treatment of dermatomycoses, skin candidiasis, seborrhoeic dermatitis. /Segal R., David M., Ingber A., Lurie R, Sandbank M.: Treatment with bifonazole shampoo for seborrhea and seborrheic dermatitis, 1992; SoyinkaF.: Bifonazole in the treatment of fungal skin infections in the tropics: a clinical and mycological study, 1987/.
  • the present invention solves the composition and preparation of the dermatological topical compositions - shampoos, which contain, as the active substances, substances with the fungistatic to fungicidal activity against the dermatophytes, yeasts, and moulds.
  • compositions in accordance with the invention are topical systems of a certain viscosity, destined to be applied to the skin (haired head skin) with a local effect.
  • They are solutions that contain, as the active substances, azole derivatives, or azole derivatives in combination with piroctone olamine, sulphoconcentrol, zinc piritione in a suitable vehicle and other auxiliary substances, such as primary and secondary surfactants, viscosity regulators, emollients, protectives, hydrating substances, and alpantha.
  • alkyl-ether-sulphate was used as the primary surfactant. Compared to alkylsulphates, it has a more stable colour, better solubility, is a good solvent for non-polar compounds that can be present in the composition.
  • a derivative of betaine was used as the vehicle for the dermatological non-irritating shampoos.
  • the betaine derivatives form anionic and cationic surfactants, depending on the pH of the system. These active substances have an antistatic effect, have a mild effect to the skin, being compatible with electrolytes, detergents and germicidal substances, and are non-toxic.
  • the process of preparation in accordance with this invention comprises processing of the antimycotic active substance with a carrier - propylene glycol, adding an emollient - lactic acid for keeping the pH value within the range from 4.0 to 6.0 as this makes the hair more resistant to damage and the shampoos with a lower pH value are less irritating. Subsequently, primary and secondary surfactants, viscosity regulating substances and hydration regulating substances - emollients - are added.
  • the alpantha i.e. panthenol encapsulated on an alantoin core
  • panthenol encapsulated on an alantoin core the combined protection and healing characteristics - epithelization combined with the skin nutrition - are reached.
  • the combined action of both substances manifests itself more effectively than the separate effects of either of the constituents.
  • the preparation in accordance with the invention has been clinically tested and it has shown remarkable anti-microbial and anti-mycotic effects.
  • Evaluating criterion for the anti-microbial effects has been expressed as the logarithm of the reduction in the number of the microorganisms versus the initial value of the inoculum. In all the events the results met the prescribed reduction.
  • the topical composition has cidal effects, based on the obtained test results.
  • topical compositions containing the anti-mycotic active substance in the treatment of superficial skin infections such as epidermophytia corporis, epidermophytia manuum, epidermophytia peduum, epidermophytia interdigitalis, skin candidiasis, pityriasis versicolor, and erythrasma has been confirmed in numerous multi-centric controlled studies and compared with other topical preparations.
  • Active substance Bifonazolum 2.5 % by weight
  • Vehicle composition Lauromacrogoli natrii sulfas 20 % by weight
  • the vehicle composition is the same as in Example 1.
  • the auxiliary materials are the same as in Example 1.
  • the vehicle composition is the same as in Example 2.
  • the auxiliary materials are the same as in Example 2.
  • the vehicle composition is the same as in Example 3.
  • the auxiliary materials are the same as in Example 3.
  • the vehicle composition is the same as in Example 1.
  • the auxiliary materials are the same as in Example 1.
  • the vehicle composition is the same as in Example 2.
  • the auxiliary materials are the same as in Example 2.
  • the vehicle composition is the same as in Example 3.
  • the auxiliary materials are the same as in Example 3.
  • the vehicle composition is the same as in Example 1.
  • the auxiliary materials are the same as in Example 1.
  • the vehicle composition is the same as in Example 2.
  • the auxiliary materials are the same as in Example 2.
  • the vehicle composition is the same as in Example 3.
  • the auxiliary materials are the same as in Example 3.
  • Zincpyrithione 0.5 % by weight
  • the vehicle composition is the same as in Example 1.
  • the auxiliary materials are the same as in Example 1.
  • Example 15 The vehicle composition is the same as in Example 2.
  • the auxiliary materials are the same as in Example 2.
  • Zincpyrithione 4.5 % by weight
  • the vehicle composition is the same as in Example 3.
  • the auxiliary materials are the same as in Example 3.
  • Zincpyrithione 0.5 % by weight
  • the vehicle composition is the same as in Example 1.
  • the auxiliary materials are the same as in Example 1.
  • the vehicle composition is the same as in Example 2.
  • the auxiliary materials are the same as in Example 2.
  • Zincpyrithione 4.5 % by weight
  • Example 3 The vehicle composition is the same as in Example 3.
  • the auxiliary materials are the same as in Example 3.
  • Examples 16, 17, 18 -Preparative method The same procedure as in Example 1.
  • the invention is usable in the pharmaceutical industry, in the production of the dermatological topical preparations destined to be applied to the hair covering the head skin and in the treatment of the fungal infections.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

Dermatological topical compositions, which contain, as the active substance, at least one substance from the group including bifonazole, zincpyrithione, piroctone olamine, sulfoconcentrol, or a mixture of some of the said active substances, alpantha and auxiliary substances, and a process of preparation, in which a viscous topical liquid having antimycotic effect is prepared, which is destined for use in the treatment of the skin fungal infections caused by moulds and yeasts.

Description

Dermatological topical compositions and a process for the preparation thereof
Technical Field
The invention pertains to the field of manufacture of the dermatological topical compositions based on use of substances having antimycotic activity, which are characterized in fungistatic to fungicidal activity against dermatophytes, yeasts, and moulds.
Background Art
The group of therapeutic compositions in the topic form, destined to be applied to the hair covering the head skip includes a variety of shampoos, lotions, hair solutions, and other types of preparations which, after having been applied, are washed off with water. Upon application, they form foam with water. They can have the structure of an emulsion, suspension, solution, with one or more active substances in a suitable carrier and other auxiliary substances, such as surfactants, anti-microbial substances, stabilizers, viscosity regulators, antioxidants, etc.
The shampoos contain three types of components: primary surfactants, secondary surfactants, and auxiliary substances. The group of primary surfactants is responsible for the detergency and cleaning of hair, the secondary ones support the detergency. The substances from the third group are added in order to reach special effects and include anti-microbial active substances against the occurrence of dandruff, substances for sedation and maintaining balance of the head skin, etc.
Alkyl-sulfates and alkyl-ether-sulfates are used as the basic surfactants Milan Chalabala et al, Technologie leku ("Medicament Technology"), 1997/.
The secondary group of surfactants is added to improve the detergency, to foster the foam stability, to increase the solubilization of the fragrances and hydrophobic substances. Use of secondary anionic and non-ionic surfactants in shampoos facilitates the detergency of the primary surfactants, but they tend to hydrolyze while being stored, and when applied to the hair the same becomes rough and easily gets a static charge. Currently, the surface mycoses are being treated with azole derivatives in compliance with the WHO recommendations. In its chemical structure bifonazole is similar to clotrimazole, econazolej miconazole or climbazole, but - unlike them - it does not contain any halogen, and is therefore suitable for the skin. The fungicidal activity has been demonstrated in numerous clinical studies in the treatment of dermatomycoses, skin candidiasis, seborrhoeic dermatitis. /Segal R., David M., Ingber A., Lurie R, Sandbank M.: Treatment with bifonazole shampoo for seborrhea and seborrheic dermatitis, 1992; SoyinkaF.: Bifonazole in the treatment of fungal skin infections in the tropics: a clinical and mycological study, 1987/.
Fungistatic activity has been demonstrated with the substances applied to inhibit the dandruff. Sulphoconcentrol, salicylic acid in combination with hexachlorophene, selenium disulphide, zinc pyrithione, piroctone olamine /Schrader K.H.: Wirkung und Nebenwirkung moderner Antischuppenpraparate, 1982/. Recently, substantial changes in the composition of shampoos have occurred. There has been a move to more sophisticated preparations that wash the hair, giving it a natural look, gloss, elasticity, and touch. Much emphasized is a mild effect on the head skin and the eyes. /Patents of the cosmetic companies Unilever, Gillete, Colgate- Palmolive./
Trends in dermatology aim at better functionality of the shampoos with effects against the formation of dandruff and for the treatment of fungal infections. During application of the preparations, neither resistance nor decrease in the sensitivity of dermatophytes may occur.
Disclosure of the Invention
The present invention solves the composition and preparation of the dermatological topical compositions - shampoos, which contain, as the active substances, substances with the fungistatic to fungicidal activity against the dermatophytes, yeasts, and moulds.
The dermatological compositions in accordance with the invention are topical systems of a certain viscosity, destined to be applied to the skin (haired head skin) with a local effect. They are solutions that contain, as the active substances, azole derivatives, or azole derivatives in combination with piroctone olamine, sulphoconcentrol, zinc piritione in a suitable vehicle and other auxiliary substances, such as primary and secondary surfactants, viscosity regulators, emollients, protectives, hydrating substances, and alpantha.
An alkyl-ether-sulphate was used as the primary surfactant. Compared to alkylsulphates, it has a more stable colour, better solubility, is a good solvent for non-polar compounds that can be present in the composition.
As the secondary amphoteric surfactant, a derivative of betaine was used as the vehicle for the dermatological non-irritating shampoos. The betaine derivatives form anionic and cationic surfactants, depending on the pH of the system. These active substances have an antistatic effect, have a mild effect to the skin, being compatible with electrolytes, detergents and germicidal substances, and are non-toxic.
By joint action of the anti-mycotic active substance and auxiliary substances used in the dermatological shampoo in accordance with this invention sedation, hydration, and restoration of the skin balance are reached. The well-balanced combination of the ratio between the active and auxiliary substances in accordance with the invention the actual acidity of the preparation is kept at pH - 5.0, which makes the hair more resistant against the damage, adds gloss to the hair, the hair dries faster, remaining under control. It is important that the selected auxiliary substances in the dosage employed do not irritate the eyes and the skin of the head.
The process of preparation in accordance with this invention comprises processing of the antimycotic active substance with a carrier - propylene glycol, adding an emollient - lactic acid for keeping the pH value within the range from 4.0 to 6.0 as this makes the hair more resistant to damage and the shampoos with a lower pH value are less irritating. Subsequently, primary and secondary surfactants, viscosity regulating substances and hydration regulating substances - emollients - are added.
By using the alpantha, i.e. panthenol encapsulated on an alantoin core, the combined protection and healing characteristics - epithelization combined with the skin nutrition - are reached. The combined action of both substances manifests itself more effectively than the separate effects of either of the constituents. The preparation in accordance with the invention has been clinically tested and it has shown remarkable anti-microbial and anti-mycotic effects.
The anti-microbial effect has been tested in compliance with Ph. Eur. using the following strains:
Pseudomonas aeruginosa NTCC Staphylococcus aureus ATCC Candida albicans ATCC Aspergillus niger ATCC
Evaluating criterion for the anti-microbial effects has been expressed as the logarithm of the reduction in the number of the microorganisms versus the initial value of the inoculum. In all the events the results met the prescribed reduction.
Figure imgf000005_0001
Evaluation by the acceptability criteria for topical medicaments as stated in the SL - 1 Table 5.1.3.-2.
The topical composition has cidal effects, based on the obtained test results.
The effectiveness of the topical compositions containing the anti-mycotic active substance in the treatment of superficial skin infections, such as epidermophytia corporis, epidermophytia manuum, epidermophytia peduum, epidermophytia interdigitalis, skin candidiasis, pityriasis versicolor, and erythrasma has been confirmed in numerous multi-centric controlled studies and compared with other topical preparations. In the comparing clinical studies 1% bifonazole applied once a day has proved itself as effective as other topical imidazoles, such as clotrimazole, econazole, miconazole, and sulconazole, which have been administered twice a day, and as oxiconazole or naphthidine, applied once a day. It is obvious from the clinical studies that bifonazole is perspective in the child dermatitis treatment. /DeichmannB.: Bifonazol versus Miconazol, 1985, Berg D., Regel E., Harenberg HE., Plempel M.: Bifonazol and clotrimazol, 1984/
The invention is illustrated in examples below, which, however, are not limiting in any sense.
Example 1
Active substance:
Bifonazolum 5.0 % by weight
Vehicle composition:
Lauromacrogoli natrii sulfas 15 % by weight
Cocamidopropylbetainum 7 % by weight
Laureth - 3 1 % by weight
Auxiliary materials:
Propylenglycolum 1 % by weight
Acidum lacticum 0.8 % by weight
Alpantha 0.8 % by weight
Dye
Perfume 0.2 % by weight
Aqua purificata ad 100.0 % by weight
Example 2
Active substance: Bifonazolum 2.5 % by weight Vehicle composition: Lauromacrogoli natrii sulfas 20 % by weight Cocamidopropylbetainum 10 % by weight
Laureth - 3 2.5 % by weight
Auxiliary materials:
Propylenglycolum 2 % by weight
Acidum lacticum 3 % by weight
Alpantha 2.5 % by weight
Dye
Perfume 0.2 % by weight
Aqua purificata ad 100.0 % by weight
Example 3
Active substance:
Bifonazolum 4.5 % by weight
Vehicle composition:
Lauromacrogoli natrii sulfas 28 % by weight
Cocamidopropylbetainum 10 % by weight
Laureth - 3 4.5 % by weight
Auxiliary materials:
Propylenglycolum 4 % by weight
Acidum lacticum 4.9 % by weight
Alpantha 4 % by weight
Dye
Perfume 0.2 % by weight
Aqua purificata ad 100.0 % by weight
Examples 1, 2, 3 - Preparative method
In a homogenizing apparatus equipped with an anchor mixer, propylene glycol is mixed with the active substance and lactic acid. A primary surfactant is added stepwise and mixed until complete dissolution of the active substance. Under continuous mixing all remaining components of the prescribed composition, an aqueous solution of the dye and alpantha are added. Finally, the substances responsible for the viscosity of the composition are added. The whole procedure proceeds under continuous action of the mixer. During the procedure the temperature must not exceed 30 °C. The total duration of the procedure is 2 hours.
Example 4
Active substance:
Piroctone olamine 0.5 % by weight
The vehicle composition is the same as in Example 1. The auxiliary materials are the same as in Example 1.
Example 5
Active substance:
Piroctone olamine 2.5 % by weight
The vehicle composition is the same as in Example 2. The auxiliary materials are the same as in Example 2.
Example 6
Active substance:
Piroctone olamine 4.5 % by weight
The vehicle composition is the same as in Example 3. The auxiliary materials are the same as in Example 3.
Examples 4, 5, 6 - Preparative method The same procedure as in Example 1.
Example 7
Active substance:
Piroctone olamine 0.5 % by weight
Sulphoconcentrol 0.5 % by weight
The vehicle composition is the same as in Example 1. The auxiliary materials are the same as in Example 1.
Example 8
Active substance:
Piroctone olamine 2.5 % by weight
Sulphoconcentrol 2.5 % by weight
The vehicle composition is the same as in Example 2. The auxiliary materials are the same as in Example 2.
Example 9
Active substance:
Piroctone olamine 4.5 % by weight
Sulphoconcentrol 4.5 % by weight
The vehicle composition is the same as in Example 3. The auxiliary materials are the same as in Example 3.
Examples 7, 8, 9 - Preparative method The same procedure as in Example 1.
Example 10
Active substance:
Piroctone olamine 0.5 % by weight
Bifonazolum 0.5 % by weight
The vehicle composition is the same as in Example 1. The auxiliary materials are the same as in Example 1.
Example 11
Active substance:
Piroctone olamine 2.5 % by weight Bifonazolum 2.5 % by weight
The vehicle composition is the same as in Example 2. The auxiliary materials are the same as in Example 2.
Example 12
Active substance:
Piroctone olamine 4.5 % by weight
Bifonazolum 4.5 % by weight
The vehicle composition is the same as in Example 3. The auxiliary materials are the same as in Example 3.
Examples 10, 11, 12 - Preparative method The same procedure as in Example 1.
Example 13
Active substance:
Zincpyrithione 0.5 % by weight
Bifonazolum 0.5 % by weight
The vehicle composition is the same as in Example 1. The auxiliary materials are the same as in Example 1.
Example 14
Active substance:
Zincpyrithione 2.5 % by weight
Bifonazolum 2.5 % by weight
The vehicle composition is the same as in Example 2. The auxiliary materials are the same as in Example 2. Example 15
Active substance:
Zincpyrithione 4.5 % by weight
Bifonazolum 4.5 % by weight
The vehicle composition is the same as in Example 3. The auxiliary materials are the same as in Example 3.
Examples 13, 14, 15 -Preparative method The same procedure as in Example 1.
Example 16
Active substance:
Zincpyrithione 0.5 % by weight
The vehicle composition is the same as in Example 1. The auxiliary materials are the same as in Example 1.
Example 17
Active substance:
Zincpyrithione 2.5 % by weight
The vehicle composition is the same as in Example 2. The auxiliary materials are the same as in Example 2.
Example 18
Active substance:
Zincpyrithione 4.5 % by weight
The vehicle composition is the same as in Example 3. The auxiliary materials are the same as in Example 3. Examples 16, 17, 18 -Preparative method The same procedure as in Example 1.
The products of Examples 1, 2, 3, 10, 11, and 12 have undergone and complied with the above- mentioned test of anti-microbial activity.
Industrial Applicability
The invention is usable in the pharmaceutical industry, in the production of the dermatological topical preparations destined to be applied to the hair covering the head skin and in the treatment of the fungal infections.

Claims

1. Dermatological topical compositions, characterized in that they contain, as the active substance, at least one substance from the group including bifonazole, piroctone olamine, sulfoconcentrol, zincpyrithione, and mutual mixtures of said active substances, in combination with surfactants, emollients and a viscosity regulator.
2. The dermatological topical compositions according to claim 1, characterized in that they contain the active substance in an amount of from 0.1 to 5.0 % by weight, or a mutual mixture of active substances in an amount of from 0.1 to 5.0 % by weight for each active substance present.
3. The dermatological topical compositions according to claim 1 or 2, characterized in that they contain, as emollients, alpantha, which is a combination of panthenol encapsulated on an alantoin core, in an amount of from 0.1 to 5.0 % by weight, lactic acid in an amount of from
0.1 to 5.0 % by weight, and propylene glycol in an amount of from 0.1 to 5.0 % by weight.
4. The dermatological topical compositions according to any of claims 1 to 3, characterized in that they contain, as a primary surfactant, lauromacrogoli natrii sulfas in an amount of from 10.0 to 30.0 % by weight, in combination with the amphoteric surfactant cocamidopropylbetainum in an amount of from 6.0 to 13.0 % by weight.
5. The dermatological topical compositions according to any of claims 1 to 4, characterized in that they contain, as a viscosity regulator, laureth-3 in an amount of from 0.5 to 5.0 % in weight.
6. The dermatological topical compositions according to any of claims 1 to 5, characterized in that they contain, as a solubilizing agent for the active substances, propylene glycol in an amount of 0.1 to 5.0 % by weight.
7. The dermatological topical compositions according to any of claims 1 to 6, characterized in that lactic acid adjusts the actual acidity in the range of pH 4.0 to 6.0.
8. A process for the preparation of the dermatological topical compositions according to any of claims 1 to 7, characterized in that a solution of the active substance or of a mixture of active substances with the solubilizing agent is prepared, actual acidity is adjusted, followed by adding a primary surfactant, an amphoteric surfactant, emollients, a perfume, an aqueous solution of a dye and alpantha, and a viscosity regulator, the temperature during the process not exceeding 30 °C.
PCT/SK2003/000002 2002-01-21 2003-01-17 Dermatological topical compositions and a process for the preparation thereof WO2003059297A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003216034A AU2003216034A1 (en) 2002-01-21 2003-01-17 Dermatological topical compositions and a process for the preparation thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SKPP0103-02 2002-01-21
SK103022002 2002-01-21

Publications (3)

Publication Number Publication Date
WO2003059297A2 true WO2003059297A2 (en) 2003-07-24
WO2003059297A3 WO2003059297A3 (en) 2003-12-18
WO2003059297A8 WO2003059297A8 (en) 2004-04-15

Family

ID=20436044

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SK2003/000002 WO2003059297A2 (en) 2002-01-21 2003-01-17 Dermatological topical compositions and a process for the preparation thereof

Country Status (2)

Country Link
AU (1) AU2003216034A1 (en)
WO (1) WO2003059297A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008018085A2 (en) * 2006-08-10 2008-02-14 Naveh Pharma (1996) Ltd. Compositions and methods for treating dermatological abscesses
WO2009019509A2 (en) * 2007-08-03 2009-02-12 York Pharma Plc Improving skin barrier function
EP2222319A2 (en) * 2007-11-17 2010-09-01 Bayer Consumer Care AG Topical drugs for use in antifungal therapy
DE102010013275A1 (en) * 2010-03-29 2011-09-29 Beiersdorf Ag Microbiologically stable, application-friendly W / O preparations

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227164A (en) * 1990-01-29 1993-07-13 Lundmark Larry D Hair treatment composition and method
WO1997003637A1 (en) * 1995-07-14 1997-02-06 Unilever Plc Antimicrobial hair treatment composition
DE19537509A1 (en) * 1995-09-27 1997-04-10 Egsto Pharm Pharmazeutische Pr Prods. for treating irritated skin
WO1998052518A1 (en) * 1997-07-02 1998-11-26 Neutrogena Corporation Methods for using compositions containing dichlorophenyl imidazoldioxolan to treat seborrheic dermatitis, dandruff, psoriasis, and acne, and compositions thereof
WO1999030675A1 (en) * 1997-12-18 1999-06-24 Johnson & Johnson Consumer Companies, Inc. Methods for improving the health of hair and scalp
WO2000061101A1 (en) * 1999-04-12 2000-10-19 Hans Schwarzkopf Gmbh & Co. Kg Aqueous cosmetic preparations containing tartaric-acid or citric-acid esters of alkyl polyglucose and cationic or amphoteric polymers
WO2000066072A1 (en) * 1999-05-03 2000-11-09 The Procter & Gamble Company Shampoos providing a superior combination of anti-dandruff efficacy and conditioning
FR2795955A1 (en) * 1999-07-09 2001-01-12 Oreal Composition for treatment of dandruff contains antidandruff agent and amino fructane
EP1093787A1 (en) * 1999-09-29 2001-04-25 L'oreal Composition for treating dandruffs in hair and scalp based on a pyridinethione salt, an insoluble conditioning agent and an acrylic terpolymer
WO2001043706A1 (en) * 1999-12-18 2001-06-21 Cognis Deutschland Gmbh & Co. Kg Use of nanoscale active anti-dandruff ingredients
WO2001047481A1 (en) * 1999-12-28 2001-07-05 Pharmaskin Ltd. Composition for the treatment of dandruff
WO2001076552A2 (en) * 2000-04-11 2001-10-18 Noveon Ip Holdings Corp. Stable aqueous surfactant compositions
WO2002000178A1 (en) * 2000-06-27 2002-01-03 Unilever Plc Compositions containing a metal pyrithione
US20020012228A1 (en) * 1998-12-04 2002-01-31 Sony Corporation. Cooling device, cooling method, and electronic apparatus
WO2002032381A2 (en) * 2000-10-10 2002-04-25 The Procter & Gamble Company Packaged scalp cosmetic compositions
EP1226814A1 (en) * 1999-11-04 2002-07-31 Kao Corporation Detergent composition

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227164A (en) * 1990-01-29 1993-07-13 Lundmark Larry D Hair treatment composition and method
WO1997003637A1 (en) * 1995-07-14 1997-02-06 Unilever Plc Antimicrobial hair treatment composition
DE19537509A1 (en) * 1995-09-27 1997-04-10 Egsto Pharm Pharmazeutische Pr Prods. for treating irritated skin
WO1998052518A1 (en) * 1997-07-02 1998-11-26 Neutrogena Corporation Methods for using compositions containing dichlorophenyl imidazoldioxolan to treat seborrheic dermatitis, dandruff, psoriasis, and acne, and compositions thereof
WO1999030675A1 (en) * 1997-12-18 1999-06-24 Johnson & Johnson Consumer Companies, Inc. Methods for improving the health of hair and scalp
US20020012228A1 (en) * 1998-12-04 2002-01-31 Sony Corporation. Cooling device, cooling method, and electronic apparatus
WO2000061101A1 (en) * 1999-04-12 2000-10-19 Hans Schwarzkopf Gmbh & Co. Kg Aqueous cosmetic preparations containing tartaric-acid or citric-acid esters of alkyl polyglucose and cationic or amphoteric polymers
WO2000066072A1 (en) * 1999-05-03 2000-11-09 The Procter & Gamble Company Shampoos providing a superior combination of anti-dandruff efficacy and conditioning
FR2795955A1 (en) * 1999-07-09 2001-01-12 Oreal Composition for treatment of dandruff contains antidandruff agent and amino fructane
EP1093787A1 (en) * 1999-09-29 2001-04-25 L'oreal Composition for treating dandruffs in hair and scalp based on a pyridinethione salt, an insoluble conditioning agent and an acrylic terpolymer
EP1226814A1 (en) * 1999-11-04 2002-07-31 Kao Corporation Detergent composition
WO2001043706A1 (en) * 1999-12-18 2001-06-21 Cognis Deutschland Gmbh & Co. Kg Use of nanoscale active anti-dandruff ingredients
WO2001047481A1 (en) * 1999-12-28 2001-07-05 Pharmaskin Ltd. Composition for the treatment of dandruff
WO2001076552A2 (en) * 2000-04-11 2001-10-18 Noveon Ip Holdings Corp. Stable aqueous surfactant compositions
WO2002000178A1 (en) * 2000-06-27 2002-01-03 Unilever Plc Compositions containing a metal pyrithione
WO2002032381A2 (en) * 2000-10-10 2002-04-25 The Procter & Gamble Company Packaged scalp cosmetic compositions

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008018085A2 (en) * 2006-08-10 2008-02-14 Naveh Pharma (1996) Ltd. Compositions and methods for treating dermatological abscesses
WO2008018085A3 (en) * 2006-08-10 2009-05-07 Naveh Pharma 1996 Ltd Compositions and methods for treating dermatological abscesses
WO2009019509A2 (en) * 2007-08-03 2009-02-12 York Pharma Plc Improving skin barrier function
WO2009019509A3 (en) * 2007-08-03 2009-04-30 York Pharma Plc Improving skin barrier function
EP2222319A2 (en) * 2007-11-17 2010-09-01 Bayer Consumer Care AG Topical drugs for use in antifungal therapy
DE102010013275A1 (en) * 2010-03-29 2011-09-29 Beiersdorf Ag Microbiologically stable, application-friendly W / O preparations

Also Published As

Publication number Publication date
AU2003216034A8 (en) 2003-07-30
AU2003216034A1 (en) 2003-07-30
WO2003059297A8 (en) 2004-04-15
WO2003059297A3 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
US6207142B1 (en) Compositions containing an antifungal and a cationic agent
US20080317737A1 (en) Drug combination for the treatment of skin disorders
AU726145B2 (en) Compositions containing an antifungal and a sulfur compound
US20110082118A1 (en) Onychomycosis Treatment Delivery System
JP2020525428A (en) Topical composition
SK63799A3 (en) Body or hair cleansing composition containing an antifungal and a phospholipid and process for the preparing such composition
US20110076261A1 (en) Antifungal Drug Delivery System
AU2015419256B2 (en) Personal care compositions
KR20010020598A (en) Methods for using compositions containing dichlorophenyl imidazoldioxolan to treat seborrheic dermatitis, dandruff, psoriasis, and acne, and compositions thereof
EP3723714B1 (en) Propanediol monoacetate mononitrate
WO2003059297A2 (en) Dermatological topical compositions and a process for the preparation thereof
HU226955B1 (en) Use of 1-hydroxy-2-pyridone for the production of a medicinal shampoo for the treatment of seborrheic dermatitis
JPWO2004028502A1 (en) Cleaning composition containing antifungal and antibacterial agents
JP3568077B2 (en) Antibacterial hypoallergenic cosmetics
CN101485618B (en) Composition and application thereof as scurf-eliminating and itch-stopping agent
US20170246095A1 (en) Topical sanitizer that includes avenanthramides
JP2006335768A (en) Cleansing composition containing antifungal and antibacterial agents
SK286288B6 (en) Dermatological topical preparations and method for their preparation
CN114869801B (en) Hair care compositions
JP2001278728A (en) Cosmetic
CN100589789C (en) Shampoo composition for removing dandruff and relieving itching
JP2010024183A (en) Antimicrobial composition and cosmetic product
EP3570813B1 (en) Hair care composition
KR100469652B1 (en) Alkali metal soap compound for hair containing anti-fungal agents
JP2003160450A (en) Shampoo composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PV2003-3120

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: PV2003-3120

Country of ref document: CZ

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 30/2003 UNDER (72, 75) THE NAME SHOULD READ "VARGA, IVAN"

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载